Also found in: Dictionary, Thesaurus, Encyclopedia.

factor IX (human)

AlphaNine SD, Immune VH (CA), Mononine

factor IX (recombinant)


factor IX complex

Bebulin VH, Defix (UK), Hipfix (UK), Octaplex (CA), Profilnine SD, Proplex T (heat-treated), Replenine (UK)

Pharmacologic class: Blood modifier

Therapeutic class: Antihemophilic

Pregnancy risk category C


Converts fibrinogen to fibrin, increasing levels of clotting factors


Powder for injection: Various strengths; units specified on label

Indications and dosages

Factor IX deficiency (hemophilia B or Christmas disease); anticoagulant overdose

Adults and children: Dosage individualized; drug administered I.V. Use following equations to calculate approximate units needed:

Human product-1 unit/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal

Recombinant product-1.2 units/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal

Proplex T-0.5 unit/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal

Off-label uses

• Hepatic dysfunction

• Esophagitis

• Unspecified GI hemorrhage (human product)


• Hypersensitivity to mouse or hamster protein (with BeneFix)

• Fibrinolysis


Use cautiously in:

• recent surgery

• pregnant patients

• children younger than age 6 (safety and efficacy not established).


Give by slow I.V. infusion. Average infusion rate is 100 units (2 to 3 ml)/minute; don't exceed 10 ml/minute.

• If prescribed, administer hepatitis B vaccine before giving factor IX.

• Know that dosage is highly individualized according to degree of factor IX deficiency, patient's weight, and bleeding severity.

• Don't use glass syringe. Don't shake reconstituted solution or mix with other I.V. solutions.

Adverse reactions

CNS: light-headedness, paresthesia, headache

CV: blood pressure changes, thromboembolic reactions, myocardial infarction (MI)

EENT: allergic rhinitis

GI: nausea, vomiting

Hematologic: disseminated intravascular coagulation (DIC)

Respiratory: pulmonary embolism

Skin: rash, flushing, diaphoresis, pruritus, urticaria

Other: altered taste, fever, chills, burning sensation in jaw and skull, pain at I.V. injection site, hypersensitivity reactions including anaphylaxis


Drug-drug. Aminocaproic acid: increased risk of thrombosis

Patient monitoring

• Be aware that factor IX complex may transmit hepatitis.

• Closely monitor vital signs during infusion.

Observe for hemolytic reaction. If it occurs, stop infusion, flush line with saline solution, and notify prescriber immediately.

• Monitor I.V. injection site closely.

Monitor coagulation studies closely. Know that drug may cause thromboembolic disorders, including MI and DIC.

Patient teaching

• Inform patient that drug may transmit diseases.

Tell patient to immediately report signs and symptoms of hypersensitivity reaction, including rash, hives, tightness in chest, wheezing, shortness of breath, and swelling of throat or lips.

Advise patient to immediately report unusual bleeding or bruising.

• Caution patient to avoid activities that can cause injury.

• Tell patient to wear medical identification stating that he has a blood-clotting disorder.

• Instruct patient to notify surgeon or dentist of his blood-clotting disorder before surgery or invasive dental procedures.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.


A recombinant factor IX for treating spontaneous bleeds (prophylaxis) and preventing bleeds during surgery and postoperatively in patients with haemophilia.

Adverse effects
Dizziness, headache, altered taste, lightheadedness, nausea, cellulitis, phlebitis, injection-site reaction, neutralising antibodies resulting in factor IX inhibition.


Recombinant coagulation factor IX Hematology A recombinant factor IX for treating spontaneous bleeds, prophylaxis, and preventing bleeds during surgery and postoperatively in Pts with hemophilia B


A brand name for recombinant human Factor IX formulated as a drug.
References in periodicals archive ?
Last year Ben Franklin invested $100,000 in Lancaster-based BeneFix, whihc makes insurance-benefit quoting software.
"Health benefits is a complicated industry with a lot of moving parts in it and BeneFix is using technology to make it more transparent, easier and quicker," Fafel said.
BeneFix's founder and CEO, Matthew Ranauro, said the company plans to use the investment to continue development of its software and focus on streamlining its product.
BeneFix is on track to be the benefit software used by 50 percent of small-business owners in the state to provide medical benefits to their employees, according to Ranauro.
He took that opportunity to extend his full-time paid internship at Benefix past summer vacation and has been working as part of Benefix's team of web engineers based in Lancaster, Colorado and India.
This interview has been edited for clarity and length.What attracted you to Benefix?
It seemed like Benefix was addressing something that was a real issue, that they were doing really good work.
I wanted everything that Benefix is: I wanted a small startup that's focused on addressing a real issue, and they're in my hometown.
How did the Convert to Code workshop at Benefix on Sept.
Since PREVENAR, the predecessor of PREVENAR13, was launched in Japan in February 2010 by Wyeth K.K., now Pfizer, PREVENAR13 in October 2013 by Pfizer, BENEFIX 500, 1000, 2000 in January 2010 by Wyeth K.K., and 3000 in December 2013 by Pfizer, Takeda has been distributing the products.
Pfizer and Takeda will work closely to smoothly implement the marketing transfer of PREVENAR13 and BENEFIX. The companies will remain committed to contributing to healthcare by providing drugs that meet the needs of patients and medical professionals.